Aptose Biosciences Inc. Quarterly Net Cash Provided by (Used in) Operating Activities in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
Summary
Aptose Biosciences Inc. quarterly/annual Net Cash Provided by (Used in) Operating Activities history and growth rate from Q1 2017 to Q3 2024.
  • Aptose Biosciences Inc. Net Cash Provided by (Used in) Operating Activities for the quarter ending September 30, 2024 was -$10.4M, a 1.52% increase year-over-year.
  • Aptose Biosciences Inc. Net Cash Provided by (Used in) Operating Activities for the twelve months ending September 30, 2024 was -$37.2M, a 15.5% increase year-over-year.
  • Aptose Biosciences Inc. annual Net Cash Provided by (Used in) Operating Activities for 2023 was -$44.6M, a 38% decline from 2022.
  • Aptose Biosciences Inc. annual Net Cash Provided by (Used in) Operating Activities for 2022 was -$32.3M, a 25.4% increase from 2021.
  • Aptose Biosciences Inc. annual Net Cash Provided by (Used in) Operating Activities for 2021 was -$43.3M, a 27.8% decline from 2020.
Net Cash Provided by (Used in) Operating Activities, Trailing 12 Months (USD)
Net Cash Provided by (Used in) Operating Activities, Quarterly (USD)
Net Cash Provided by (Used in) Operating Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$37.2M -$10.4M +$160K +1.52% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$37.3M -$5.78M +$7.73M +57.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$45.1M -$11.8M -$461K -4.08% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q4 2023 -$44.6M -$9.25M -$598K -6.91% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-26
Q3 2023 -$44M -$10.5M -$3.56M -51% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$40.4M -$13.5M -$6.46M -91.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$34M -$11.3M -$1.66M -17.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q4 2022 -$32.3M -$8.65M +$7.39M +46.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-26
Q3 2022 -$39.7M -$6.98M +$1.08M +13.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$40.8M -$7.05M +$1.78M +20.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$42.6M -$9.65M +$731K +7.05% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$43.3M -$16M -$5.7M -55.1% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-24
Q3 2021 -$37.6M -$8.06M +$211K +2.55% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$37.8M -$8.83M -$1.66M -23.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-02
Q1 2021 -$36.2M -$10.4M -$2.27M -27.9% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$33.9M -$10.3M -$4.12M -66% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-22
Q3 2020 -$29.8M -$8.27M -$3.09M -59.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$26.7M -$7.16M -$1.9M -36% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 -$24.8M -$8.11M -$3.24M -66.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-04
Q4 2019 -$21.6M -$6.23M -$729K -13.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-23
Q3 2019 -$20.8M -$5.18M -$716K -16% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$20.1M -$5.27M +$3.91M +42.6% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 -$24M -$4.87M -$820K -20.2% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-05
Q4 2018 -$23.2M -$5.5M -$2.62M -91.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-10
Q3 2018 -$20.6M -$4.47M -$2.4M -116% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 -$18.2M -$9.18M -$6.55M -249% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 -$11.6M -$4.05M -$1.41M -53.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 -$10.2M -$2.88M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$2.07M Jul 1, 2017 Sep 30, 2017 8-K 2019-03-12
Q2 2017 -$2.63M Apr 1, 2017 Jun 30, 2017 8-K 2019-03-12
Q1 2017 -$2.65M Jan 1, 2017 Mar 31, 2017 8-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.